Copenhagen, Denmark, March 30, 2020 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) has today, as set out in Section 38 in the Danish Capital Markets Act, received the following major shareholder notification resulting from the increase in the Company’s share capital, registered today with the Danish Business Authority:

Johnson & Johnson Innovation – JJDC, Inc. has made a notification that as per March 30, 2020 they continue to hold 1,844,086 shares, which now corresponds to 3.16% of the share capital and voting rights in the Company.

About Bavarian Nordic
Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA, also for the protection against monkeypox. Our commercial product portfolio furthermore contains market-leading vaccines against rabies and tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an investigational Ebola vaccine, licensed to Janssen. For more information visit www.bavarian-nordic.com.

Contacts
Thomas Duschek
Investor Relations & Communications (EU)
Tel: +45 30 66 35 99

Graham Morrell, Paddock Circle Advisors (US)
graham@paddockcircle.com
Tel: +1 781 686 9600

Company Announcement no. 18 / 2020

Attachment

  • 2020-18-en

© OMX, source OMX